Patient-level comparison of heart failure patients in clinical phenotype and prognosis from China and Sweden

Feng, Yongzeng; Chen, Xiaojing; Schaufelberger, Maria; Zhang, Qing; Fu, Michael

doi:10.1186/s12872-022-02540-w

Cited by 3 publications

(1 citation statement)

References 44 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International registries have highlighted their marked differences between Asian and Western countries (online supplemental table S3). [37][38][39][40] The international collaborative study with the WET-HF registry and the Hull Lifelab registry demonstrated that the patients in the Japanese cohort had lower prevalence of ischaemic heart disease and chronic lung disease, lower body mass index, and longer length of hospital stay than those in the UK. 41 British patients had substantially higher mortality even after adjusting for plasma NT-pro BNP and other prognostic indicators.…”

Section: Assessment Of Hf Practices In Japanmentioning

confidence: 99%

Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients

Shiraishi,

Ikemura,

Urashima

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionThe current guidelines strongly recommend early initiation of multiple classes of cardioprotective drugs for patients with heart failure with reduced ejection fraction to improve prognosis and health status. However, evidence on the optimal sequencing of approved drugs is scarce, highlighting the importance of individualised treatment plans. Registry data indicate that only a portion of these patients can tolerate all four recommended classes, underscoring the need to establish the favoured sequence when using these drugs. Additionally, the choice between long-acting and short-acting loop diuretics in the present era remains uncertain. This is particularly relevant given the frequent use of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter 2 inhibitor, both of which potentiate natriuretic effects.Methods and analysisIn a prospective, randomised, open-label, blinded endpoint method, LAQUA-HF (Long-acting vs short-acting diuretics and neurohormonal Agents on patients’ QUAlity-of-life in Heart Failure patients) will be a 2×2 factorial design, with a total of 240 patients randomised to sacubitril/valsartan versus dapagliflozin and torsemide versus furosemide in a 1:1 ratio. Most enrolment sites have participated in an ongoing observational registry for consecutive patients hospitalised for heart failure involved dedicated study coordinators, and used the same framework to enrol patients. The primary endpoint is the change in patients’ health status over 6 months, defined by the Kansas City Cardiomyopathy Questionnaire. Additionally, clinical benefit at 6 months defined as a hierarchical composite endpoint will be assessed by the win ratio as the secondary endpoint.Ethics and disseminationThe medical ethics committee Keio University in Japan has approved this trial. All participants provide written informed consent prior to study entry. The results of this trial will be disseminated in one main paper and additional papers on secondary endpoints and subgroup analyses.Trial registration numberUMIN000045229

show abstract

Section: Assessment Of Hf Practices In Japanmentioning

confidence: 99%

Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients

Shiraishi,

Ikemura,

Urashima

et al. 2024

BMJ Open

View full text Add to dashboard Cite

show abstract

Parameter Extraction Algorithm of Cardiovascular Disease Related Physical Signs Based on Photoplethysmography

田¹

2023

JSTA

View full text Add to dashboard Cite

Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study

Ruiz-García

Serrano-Cumplido

Cervantes

et al. 2023

JCM

View full text Add to dashboard Cite

Introduction and objectives: Heart failure (HF) is a major health problem that causes high mortality and hospitalization rates. This study aims to determine the HF prevalence rates in populations aged both ≥18 years and ≥50 years and to assess its association with cardiovascular diseases and chronic kidney disease. Methods: A cross-sectional observational study was conducted in a primary care setting, with a population-based random sample of 6588 people aged 18.0–102.8 years. Crude and adjusted prevalence rates of HF were calculated. The associations of renal and cardiometabolic factors with HF were assessed in both populations using univariate, bivariate and multivariate analysis. Results: The HF crude prevalence rates were 2.8% (95%CI: 2.4–3.2) in adults (≥18 years), and 4.6% (95%CI: 4.0–5.3) in the population aged ≥ 50 years, without significant differences between males and females in both populations. The age- and sex-adjusted prevalence rates were 2.1% (male: 1.9%; female: 2.3%) in the overall adult population, and 4.5% (male: 4.2%; female: 4.8%) in the population aged ≥ 50 years, reaching 10.0% in the population aged ≥ 70 years. Atrial fibrillation, hypertension, low estimated glomerular filtration rate (eGFR), coronary heart disease (CHD), stroke, sedentary lifestyle, and diabetes were independently associated with HF in both populations. A total of 95.7% (95%CI: 92.7–98.6) of the population with HF had an elevated cardiovascular risk. Conclusions: This study reports that HF prevalence increases from 4.5% in the population over 50 years to 10% in the population over 70 years. The main clinical conditions that are HF-related are sedentary lifestyle, atrial fibrillation, hypertension, diabetes, low eGFR, stroke, and CHD.

show abstract

Patient-level comparison of heart failure patients in clinical phenotype and prognosis from China and Sweden

Cited by 3 publications

References 44 publications

Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients

Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients

Parameter Extraction Algorithm of Cardiovascular Disease Related Physical Signs Based on Photoplethysmography

Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study

Contact Info

Product

Resources

About